You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
First-time mothers who did not request pain relief during labor were more likely to carry a rare variant in a potassium channel-coding gene.
Functional genomics firm The DNA Company acquired digital therapeutics app My Pain Sensei, giving it an AI development platform and a Health Canada medical device license.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In PLOS this week: alternatively spliced form of FBXO38 contributes to chronic obstructive pulmonary disease, evolution of the avian influenza virus H9N2, and more.
The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.
University College London researchers sequenced a woman who realized late in life that she could not feel pain, Gizmodo reports.
Two research teams find a role for PIEZO2 in touch sensitivity after injury and inflammation.
These three loci implicated skeletal and spinal cord development-linked pathways in chronic back pain.
After a series of duplication and rearrangement events, the genes involved in two key pathways producing morphine, codeine, and noscapine have clustered in the genome.
The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
Time magazine looks into how liquid biopsies are changing cancer care.
According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.